Takara Bio Europe AB and PanCryos announce licensing agreement to enable development of cell-based therapy for diabetes
Takara Bio Europe AB (TBEAB) and PanCryos have reached a licensing agreement surrounding TBEAB’s clinical-grade human embryonic stem (hES) cell lines. PanCryos has established a simplified and effective method to generate stem cell-derived, glucoseresponsive beta cells and is one of several customers in TBEAB’s new out-licensing programme.
The programme enables industrial partners to use the clinical-grade hES cells to develop and commercialize breakthrough cell therapy products for previously unmet indications.
Commenting on the agreement, Jacqueline Ameri, CEO of PanCryos said: “We are very hopeful that our extensive scientific and industry expertise, combined with TBEAB’s expertise in clinical-grade hES cell production, will put us in a position to take the crucial next step in the development of our best-in-class, commercially sustainable PanINSULA cell therapy for type 1 diabetes.”
This announcement follows TBEAB’s successful establishment of a new clinicalgrade hES cell line. The derivation work and scale-up were conducted with feeder-free and xeno-free culture conditions under a manufacturing license granted by the Swedish MPA at TBEAB’s state-of-the-art GMP manufacturing facility in Göteberg, Sweden.
